After Cantor Fitzgerald and Chardan Capital gave Nightstar Therapeutics Limited (NASDAQ: NITE) a Buy rating last month, the company received another Buy, this time from Mizuho Securities. Analyst Difei Yang reiterated a Buy rating on Nightstar Therapeutics Limited today. The company’s shares closed yesterday at $13.02.
Yang noted:
“We updated our model and increased our discount rate from 10% to 13% to account for greater risk and volatility in the biotech space. Our PT goes to $22/Reiterate Buy.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 16.5% and a 43.7% success rate. Yang covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Audentes Therapeutics, and Revance Therapeutics.
Nightstar Therapeutics Limited has an analyst consensus of Strong Buy, with a price target consensus of $37, representing a 184.2% upside. In a report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $36 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $29.55 and a one-year low of $9.59. Currently, Nightstar Therapeutics Limited has an average volume of 158K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nightstar Therapeutics PLC is a clinical-stage gene therapy company, which engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. Its pipeline includes NSR-REP1, for the treatment of choroideremia; NSR-RPGR, for the treatment of X-linked retinitis pigmentosa; and NSR-BEST1, for the treatment of vitelliform macular dystrophy. The company was founded by Robert MacLaren on July 6, 2017 and is headquartered in London, the United Kingdom.
